Story
Anthropic IPO Filing Reveals 'Founder LLC' to Retain Majority Voting Control

Summary
AI developer Anthropic plans a novel corporate structure for its public debut, creating a 'Founder LLC' to give its seven co-founders majority voting control and prioritize its public benefit mission over short-term market pressures, according to a regulatory filing.
AI startup Anthropic is structuring its initial public offering to grant its founders lasting control, a move designed to protect its mission of developing safe and beneficial AI from the demands of public markets. According to a copy of its IPO filing seen by Reuters, the company will create a new entity, the "Founder LLC," to wield 50.1% of the voting power, effectively insulating its leadership from certain shareholder pressures.
A Novel Governance Structure
The core of the plan involves the seven co-founders, including CEO Dario Amodei, who will initially comprise the Founder LLC. This group will direct a single share of Class F stock, which carries majority voting power over key corporate decisions, such as the election of some board directors.
This structure has direct implications for new investors. The filing details several other classes of stock, including Class A common stock for the public, which will have one vote per share. However, the company explicitly warns that its governance could lead to decisions that "may conflict with short-, medium-, or long-term financial interests and business performance, which may negatively impact the value of our Class A common stock."
Anthropic will also maintain its status as a Public Benefit Corporation (PBC) under Delaware law, a legal framework that allows the company to balance the financial interests of shareholders with its broader mission to benefit humanity.
Prioritizing Safety Over Profit
Anthropic frames this unusual structure as a core advantage, stating in the filing that it promotes a "culture that promotes a low-ego, truth-seeking environment." The company has already made business decisions reflecting this priority, such as choosing not to develop commercially popular image and video generation models to focus resources on research and safety.
AdFurther control is vested in a separate body, the Long-Term Benefit Trust, which will elect four of the company's board directors. Current trustees reportedly include former Federal Reserve Chair Ben Bernanke and national security expert Richard Fontaine. This multi-layered governance is designed to ensure the company's long-term adherence to its safety-first principles.
Founder Compensation and Commitments
The filing also provides a look at executive compensation and the founders' long-term plans. According to the document:
- CEO Dario Amodei's total compensation in 2025 was nearly $18 million, primarily from stock and option awards.
- Company President Daniela Amodei, his sister, was the second-highest paid executive at $16.4 million.
- The co-founders have pledged to dedicate 80% of their personal Anthropic equity to charitable causes.
The special voting power of the Founder LLC is designed to sunset over time, beginning a transition period once two or fewer co-founders remain active in the entity.
Read next
More on Stocks
Nidec Stock Tumbles Amid CEO Resignation, Planned ¥1 Trillion Impairment
Shares of Japanese motor giant Nidec Corp. extended a steep two-day selloff following reports of its CEO's planned resignation and a massive ¥1 trillion writedown linked to its struggling electric vehicle business.

Navigator Global Shares Surge on $75M Invictus Stake Sale to New York Life
The alternative asset manager's stock jumped over 8% after it announced a deal to sell a 60% stake in Invictus Capital Partners, expecting up to $75 million in total proceeds.

China Stocks Edge Higher on Policy Support Pledge; Hong Kong Slips
Mainland Chinese stocks posted modest gains after Beijing pledged further economic support, particularly for the property sector, while Hong Kong shares declined amid thin pre-holiday trading.

Hengrui Pharma Shares Rise on $2.6 Billion Obesity Drug Deal with Novo Nordisk
Jiangsu Hengrui Pharmaceuticals saw its shares climb after securing a licensing agreement with Novo Nordisk for an experimental oral obesity and diabetes drug, with the deal valued at up to $2.6 billion.